Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 363

Similar articles for PubMed (Select 22015288)

1.

Beyond trastuzumab: new treatment options for HER2-positive breast cancer.

Saini KS, Azim HA Jr, Metzger-Filho O, Loi S, Sotiriou C, de Azambuja E, Piccart M.

Breast. 2011 Oct;20 Suppl 3:S20-7. doi: 10.1016/S0960-9776(11)70289-2. Review.

PMID:
22015288
2.

Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?

Constantinidou A, Smith I.

Breast. 2011 Oct;20 Suppl 3:S158-61. doi: 10.1016/S0960-9776(11)70316-2. Review.

PMID:
22015286
3.

A systematic review of dual targeting in HER2-positive breast cancer.

Kümler I, Tuxen MK, Nielsen DL.

Cancer Treat Rev. 2014 Mar;40(2):259-70. doi: 10.1016/j.ctrv.2013.09.002. Epub 2013 Sep 11. Review.

PMID:
24080156
4.

Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.

Cameron DA, Stein S.

Nat Clin Pract Oncol. 2008 Sep;5(9):512-20. doi: 10.1038/ncponc1156. Epub 2008 Jul 1. Review.

PMID:
18594499
5.

Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer.

Guarneri V, Barbieri E, Dieci MV, Piacentini F, Conte P.

Cancer Treat Rev. 2010 Nov;36 Suppl 3:S62-6. doi: 10.1016/S0305-7372(10)70022-0. Review.

PMID:
21129613
6.

Current and future anti-HER2 therapy in breast cancer.

Vrbic S, Pejcic I, Filipovic S, Kocic B, Vrbic M.

J BUON. 2013 Jan-Mar;18(1):4-16. Review.

PMID:
23613383
7.

Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies.

Pinto AC, Ades F, de Azambuja E, Piccart-Gebhart M.

Breast. 2013 Aug;22 Suppl 2:S152-5. doi: 10.1016/j.breast.2013.07.029. Review.

PMID:
24074778
8.

Dual HER2-targeted approaches in HER2-positive breast cancer.

Ahn ER, Vogel CL.

Breast Cancer Res Treat. 2012 Jan;131(2):371-83. doi: 10.1007/s10549-011-1781-y. Epub 2011 Sep 29. Review.

PMID:
21956210
9.

Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab.

Gradishar WJ.

Ann Oncol. 2013 Oct;24(10):2492-500. doi: 10.1093/annonc/mdt217. Epub 2013 Jul 4. Review.

10.

Patients with anti-HER2 responsive disease: definition and adjuvant therapies.

Burstein HJ.

Breast. 2011 Oct;20 Suppl 3:S132-4. doi: 10.1016/S0960-9776(11)70310-1. Review.

PMID:
22015280
11.

New protein kinase inhibitors in breast cancer: afatinib and neratinib.

Zhang X, Munster PN.

Expert Opin Pharmacother. 2014 Jun;15(9):1277-88. doi: 10.1517/14656566.2014.913570. Epub 2014 Apr 30.

PMID:
24787047
12.

Pertuzumab in HER2-positive breast cancer.

Sendur MA, Aksoy S, Altundag K.

Curr Med Res Opin. 2012 Oct;28(10):1709-16. doi: 10.1185/03007995.2012.728132. Epub 2012 Oct 11. Review.

PMID:
22953713
13.

Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer.

Spector NL, Blackwell KL.

J Clin Oncol. 2009 Dec 1;27(34):5838-47. doi: 10.1200/JCO.2009.22.1507. Epub 2009 Nov 2. Review.

PMID:
19884552
14.

Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.

Nielsen DL, Kümler I, Palshof JA, Andersson M.

Breast. 2013 Feb;22(1):1-12. doi: 10.1016/j.breast.2012.09.008. Epub 2012 Oct 16. Review.

PMID:
23084121
15.

New therapies in HER2-positive breast cancer: a major step towards a cure of the disease?

Awada A, Bozovic-Spasojevic I, Chow L.

Cancer Treat Rev. 2012 Aug;38(5):494-504. doi: 10.1016/j.ctrv.2012.01.001. Epub 2012 Feb 3. Review.

PMID:
22305205
16.

New HER2-positive targeting agents in clinical practice.

Tolaney S.

Curr Oncol Rep. 2014;16(1):359. doi: 10.1007/s11912-013-0359-8. Review.

PMID:
24442625
17.

Overcoming treatment resistance in HER2-positive breast cancer: potential strategies.

Puglisi F, Minisini AM, De Angelis C, Arpino G.

Drugs. 2012 Jun 18;72(9):1175-93. doi: 10.2165/11634000-000000000-00000. Review.

PMID:
22686613
18.

Optimal sequencing of anti-HER2 therapy throughout the continuum of HER2-positive breast cancer: evidence and clinical considerations.

Harbeck N, Wuerstlein R.

Drugs. 2013 Oct;73(15):1665-80. doi: 10.1007/s40265-013-0118-z. Review.

PMID:
24127221
19.

Blockade of the HER family of receptors in the treatment of HER2-positive metastatic breast cancer.

Sachdev JC, Jahanzeb M.

Clin Breast Cancer. 2012 Feb;12(1):19-29. doi: 10.1016/j.clbc.2011.07.001. Epub 2011 Sep 8. Review.

PMID:
21903480
20.

Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.

Nahta R, O'Regan RM.

Clin Breast Cancer. 2010 Nov;10 Suppl 3:S72-8. doi: 10.3816/CBC.2010.s.015. Review.

PMID:
21115425
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk